Sign in

Mark Maurer

Chief Risk Officer at StoneX Group
Executive

About Mark Maurer

Mark Maurer, 47, is Chief Risk Officer (CRO) of StoneX Group Inc. (SNEX) since July 2021; he previously served as CEO of StoneX Markets LLC (the company’s swap-dealer), and joined StoneX in 2010 via the acquisition of The Hanley Group where he was Head of Risk . His background is anchored in derivatives risk management with a strong understanding of option portfolios . During his tenure on the executive team, StoneX delivered record FY2024 operating revenues of $3,436.2 million (+~18% YoY), net operating revenues of $1,767.2 million (+9% YoY), net income of $260.8 million (+~9% YoY), EPS (diluted) of $7.96 (+7% YoY), and achieved adjusted ROE of 17.1% . Over FY2021–FY2024, cumulative TSR (initial $100) rose from 129 to 240, with net income at $261 million and adjusted ROE at 17.1% in FY2024 .

Past Roles

OrganizationRoleYearsStrategic Impact
StoneX Group Inc.Chief Risk OfficerJul 2021–presentEnterprise risk oversight across segments; ROE-tied incentives align risk discipline with profitability
StoneX Markets LLC (swap-dealer)Chief Executive OfficerOct 2014–Jul 2021Led swap-dealer operations; built derivatives risk frameworks
The Hanley Group (acquired)Head of RiskPre-2010–2010Integrated risk capabilities post-acquisition into StoneX

External Roles

No external directorships or roles disclosed for Mark Maurer .

Fixed Compensation

ComponentFY2024 AmountNotes
Base Salary$350,000 Same as FY2023; Compensation Committee views base pay as modest vs peers
Benefits/Other$16,500 Company contributions under defined contribution plans

Performance Compensation

Executive Performance Plan (EPP) – FY2024

MetricWeightingTargetActualPayout (Nominal)Cash PaidRestricted SharesVesting
Adjusted ROE100% 15% 17.1% $1,945,829 $1,422,080 (paid FY2025) 6,922 shares; grant-date fair value $698,361 Restricted stock vests 1/3 per year over 3 years; EPP shares issued at 25% discount to market; FY2024 awards granted Dec 13, 2024 at $100.89

Performance schedule detail: payouts scale from 100% at 15% ROE, with 1.19% added per 10 bps up to 17.5% (cap $8.5M per participant) .

Long-Term Performance Incentive Plan (LTIP) – FY2024

ComponentFY2024 AmountMechanicsVesting/Payment
LTIP Earned$929,007 Cash-based plan; award accrues “Interest” each year at the higher of effective borrowing rate or adjusted ROE (3% floor, 15% cap), then multiplied by a performance adjustment based on average adjusted ROE over the multi-year period Paid after award period; accelerated/paid per termination/CoC terms (see Employment Terms)

Equity Awards – FY2024 Grants

InstrumentGrant DateQuantityExercise/PriceFair ValueVestingTerm
Stock OptionsDec 5, 2023150,000 $64.25 $3,996,000 One-fifth annually on 3rd–7th anniversaries of 12/5/2023 ~8 years, expiring 12/5/2031

Grant practices: options granted at/above market; no repricing; minimum vesting; dividends restricted until vesting; clawback provisions in plan .

Equity Ownership & Alignment

ItemDetail
Total Beneficial Ownership175,354 shares; <1% of outstanding
Vested vs UnvestedUnvested restricted shares: 19,034 total; 8,461 vest ~Dec 15, 2025; 3,651 vest ~Dec 15, 2026; 11,175 vested ~Dec 15, 2024
Options – Exercisable90,000 @ $30.00; expire 12/5/2026
Options – Unexercisable60,000 @ $30.00; expire 12/5/2026; 150,000 @ $64.25; expire 12/5/2031
Pledging/HedgingCompany prohibits short sales and “put” hedges; no explicit ban on pledging; no margin/pledge disclosure for Maurer (others noted)
Ownership GuidelinesPolicy applies to CEO and Directors (3x salary/fees); no explicit guideline disclosed for CRO

Vesting calendar suggests recurring potential liquidity windows around mid-December each year as tranches vest .

Employment Terms

ProvisionTerm
Agreement DateEmployment agreements entered March 25, 2022
Severance (No CoC)18 months base salary; 1.5× target annual bonus; pro rata bonus; prior-year accrued bonus; 18 months health benefits; subject to release and covenants
Severance (Within 12 months of CoC)24 months base salary (lump sum); 2× target annual bonus (lump sum); pro rata bonus; prior-year accrued bonus; 24 months health benefits
TriggersTermination without Cause or resignation for Good Reason; “Good Reason” includes certain salary reductions and relocation >35 miles
Non-Compete1 year post-termination; reduced to 6 months if terminated without Cause or resign for Good Reason within 12 months post-CoC
Non-Solicit1 year post-termination (employees/clients)
ClawbackCompany Clawback Policy (2021; amended 2023) and Nasdaq 5608-compliant Recovery Policy for restatement; plan-level clawbacks
280G/4999No tax gross-up; payments cut back to avoid nondeductibility/excise tax if beneficial net-of-tax

Potential Payments (Assuming Event on Sep 30, 2024)

ScenarioCash SeveranceLTIP PaymentEquity AccelerationHealth BenefitsTotal
Termination Without Cause (No CoC)$4,806,329 $3,306,221 $1,906,740 $31,995 $10,051,285
Resignation for Good Reason (No CoC)$4,806,329 $1,748,562 $1,906,740 $31,995 $8,493,626
Termination Without Cause/Good Reason After CoC$5,759,829 $3,393,721 $4,551,240 $42,660 $13,747,450
Death or Disability$1,945,829 $2,613,221 $1,906,740 $6,465,790

Change-in-control treatment under the Omnibus Plan: all outstanding options become fully exercisable, restricted stock restrictions lapse, and LTIPs become fully vested and paid (as if terminated without Cause) unless the Committee elects alternative cash-out/assumption actions .

Compensation Structure vs Performance Metrics

  • Program emphasizes performance pay: EPP (adjusted ROE) and cash LTIP (multi-year ROE/interest structure); CEO/NEO bonuses primarily formulaic; no discretionary bonuses awarded FY2024 .
  • FY2024 EPP used only adjusted ROE; schedule strictly formula-driven with caps and per-10bp increments; target multiples and thresholds clearly defined .
  • Pay versus performance disclosures show strong linkage of compensation actually paid to TSR, net income, and adjusted ROE .

Vesting Schedules and Insider Selling Pressure

  • Restricted stock from EPP vests ratably over 3 years; FY2024 tranche granted Dec 13, 2024 (FMV $100.89); subsequent tranches expected to vest around mid-December annually .
  • Options vest one-fifth annually beginning on the third anniversary of grant, creating potential exercise/settlement windows across years 2026–2030/2031 .

Equity Ownership Alignment and Pledging

  • Beneficial ownership totals 175,354 (<1%); includes 120,000 vested options and 19,034 unvested restricted shares; no margin or pledge disclosure for Maurer (others have margin accounts) .
  • Company hedging policy prohibits short sales and put options; no blanket prohibition on pledging—monitor future disclosures for any pledge usage (red flag if it emerges) .

Employment Contracts, Severance, & CoC Economics

  • Strong retention constructs: 18–24 months salary, 1.5–2.0× target bonus, pro rata bonus, health benefits, and equity/LTIP acceleration in certain cases; non-compete/non-solicit covenants enforce post-termination .
  • Shareholder-friendly features: no excise tax gross-ups; payments subject to cutback for 280G/4999; comprehensive clawbacks (restatement/misconduct/misleading market) .

Performance & Track Record

  • Company achievements under current management: record revenues ($3,436.2m), net operating revenues ($1,767.2m), net income ($260.8m), ROE 16.9% and adjusted ROE 17.1% in FY2024 .
  • Pay vs performance: cumulative TSR improved from 129 (FY2021) to 240 (FY2024), with compensation actually paid trend tracking TSR/net income/adjusted ROE .

Compensation Committee & Governance Notes

  • Committee: independent directors; no external compensation consultant; compensation decisions consider role scope and performance; EPP/LTIP administered by committee; plan prohibits option repricing; minimum vesting; dividend restrictions until vesting .
  • Say-on-Pay: 98.3% approval at 2024 meeting; say-on-frequency annual with ~94% support .

Related Party Transactions and Risk Indicators

  • No related-party transactions for executive officers/directors in FY2024 .
  • Red-flags mitigants: clawbacks and no tax gross-ups; plan-level anti-repricing; watch for any future pledging disclosures given policy latitude .

Investment Implications

  • Alignment: Maurer’s compensation is heavily performance-based (ROE-driven EPP and multi-year LTIP), reinforcing disciplined risk-adjusted returns—a positive for shareholders .
  • Supply dynamics: Three-year restricted stock vesting and phased option vesting create predictable windows that may add selling/exercise flow, particularly around mid-December and on option vest anniversaries (monitor Form 4s) .
  • Retention/CoC: Robust severance and equity acceleration reduce key-person risk but create value-transfer triggers in CoC scenarios; single-trigger option acceleration at CoC under the plan warrants consideration in M&A scenarios .
  • Governance quality: Strong say-on-pay support, clawbacks, and no repricing/gross-ups indicate good compensation hygiene; absence of pledging for Maurer is positive, though the corporate policy permits pledging—continue surveillance .